CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...

The real-world effectiveness of Monjuvi for relapsed or refractory diffuse large B-cell lymphoma in the U.S. was demonstrated ...

Historically, sickle cell anaemia has been widely neglected within its global epicentre of sub-Saharan Africa. More than ...

Arizona State University and Banner Alzheimer's Institute researchers, along with their collaborators, have discovered a surprising link between a chronic gut infection caused by a common virus and ...

The company is using its Senza5 platform to produce CAR T cells without the CD5 receptor, hoping to enable smaller doses and avoid CAR-T fratricide.

Analysis of genome-wide spatial transcriptomics data reveals cell-type specific subcellular RNA localization, and a subset of genes show significantly high correlation between spatial patterning and 3 ...

Palleon Pharmaceuticals, a company pioneering glyco-immunology drug development to treat autoimmune diseases and cancer, today announced a collaboration and license agreement with Shanghai Henlius ...

Soligenix begins confirmatory phase 3 trial of HyBryte for treatment of cutaneous T-cell lymphoma: Princeton, New Jersey Wednesday, December 18, 2024, 14:00 Hrs [IST] Soligenix, I ...

A new study published in Naturehas identified brain cells that act like “map makers,” helping animals track their position ...

FLASH2 Study opens patient enrollment PRINCETON, N.J., Dec. 16, 2024 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...

BrightPath Bio and Cellistic have entered a process development and manufacturing agreement to progress the allogeneic CAR-T ...